Biodefense Market Forecast Driven by Threat Preparedness and Global Health Security Initiatives | Valuates Reports

Biodefense Market Size
The global Biodefense revenue was US$ 1144 million in 2022 and is forecast to a readjusted size of US$ 1884.2 million by 2029 with a CAGR of 7.3% during the review period (2023-2029).

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-30B15639/Global_and_India_Biodefense_Market_Report_Forecast_2023_2029

The biodefense market is experiencing robust market growth, propelled by increasing global concerns over biological threats, pandemic preparedness, and advancements in detection and countermeasure technologies. As governments fortify national security and public health systems, the market size continues to expand, driven by multifaceted defense strategies and global cooperation.

By threat type, anthrax defenses represent the largest market share due to sustained investment in vaccines, prophylactics, and rapid response systems designed to counter historically recognized biothreats. The others category-which includes emerging threats like plague, tularemia, and smallpox variant monitoring-also holds substantial share as public health agencies broaden their protective focus. Botulism and radiation/nuclear segments contribute meaningfully to the market, supported by specialized treatment development and cross-sector emergency response protocols. Smallpox defenses remain critical due to its status as a potential bioterror weapon, supported by ongoing stockpiling and research into next-generation vaccines.

In terms of application, the US military market leads in size, with robust procurement programs for vaccines, therapeutics, sensors, and decontamination systems as part of force readiness and battlefield protection. The US civilian market holds a significant share, driven by investments in stockpile management, hospital preparedness, and rapid diagnostic deployment within health departments and emergency response networks. The non US market-encompassing international allies and global public health organizations-is the fastest-growing segment, fueled by worldwide initiatives to bolster biodefense capabilities, regulatory harmonization, and infrastructure support in low- and middle-income countries.

Overall, the biodefense market forecast indicates sustained market growth, supported by continuing innovation in countermeasures, expanding state and international programs, and heightened awareness of biological risk across civilian and military sectors.

Segment by Type

• Anthrax
• Smallpox
• Botulism
• Radiation/Nuclear
• Others

Segment by Application

• US Military Market
• US Civilian Market
• Non - US Market

By Company

Emergent Biosolutions, Hytest, GSK, Sanofi, PharmAthene, Bavarian Nordic, SIGA Technologies, Arbutus Biopharma, DynPort Vaccine, Xoma Corporation, Ichor Medical Systems, Aeolus Pharmaceuticals, Achaogen, Elusys Therapeutics, Dynavax Technologies, Cleveland BioLabs, Soligenix, Alnylam Pharmaceuticals

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-30B15639/global-and-india-biodefense

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.